TY - JOUR
T1 - Super-enhancers promote transcriptional dysregulation in nasopharyngeal carcinoma
AU - Yuan, Jiang
AU - Jiang, Yan Yi
AU - Mayakonda, Anand
AU - Huang, Moli
AU - Ding, Ling Wen
AU - Lin, Han
AU - Yu, Fenggang
AU - Lu, Yanan
AU - Loh, Thomas Kwok Seng
AU - Chow, Marilynn
AU - Savage, Samantha
AU - Tyner, Jeffrey W.
AU - Lin, De Chen
AU - Koeffler, H. Phillip
N1 - Funding Information:
This research is supported by the National Research Foundation Singapore under its Singapore Translational Research Investigator Award (NMRC/STaR/
Funding Information:
J.W. Tyner reports receiving other commercial research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Incyte, Janssen, Seattle Genetics, Syros, and Takeda and is a consultant/advisory board member for Leap Oncology. No potential conflicts of interest were disclosed by the other authors. This research is supported by the National Research Foundation Singapore under its Singapore Translational Research Investigator Award (NMRC/STaR/ 0021/2014 to H.P. Koeffler) and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC), the NMRC Centre Grant awarded to National University Cancer Institute of Singapore, the National Research Foundation Singapore, and the Singapore Ministry of Education under its Research Centres of Excellence initiatives (to H.P. Koeffler). D.-C. Lin was supported by the National Center for Advancing Translational Sciences UCLA CTSI Grant UL1TR000124 and the Tower Cancer Research Foundation. This study was also supported by the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants (grant no. MOE2014-T3-1-006 to H.P. Koeffler), the NCIS Yong Siew Yoon Research Grant through donations from the Yong Loo Lin Trust (to H.P. Koeffler), and the Terry Fox Foundation International Run Program through funds raised by the Terry Fox Singapore Run to National University Cancer Institute Singapore (NCIS; to H.P. Koeffler). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
©2017 AACR.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Nasopharyngeal carcinoma (NPC) is an invasive cancer with particularly high incidence in Southeast Asia and Southern China. The pathogenic mechanisms of NPC, particularly those involving epigenetic dysregulation, remain largely elusive, hampering clinical management of this malignancy. To identify novel druggable targets, we carried out an unbiased high-throughput chemical screening and observed that NPC cells were highly sensitive to inhibitors of cyclin-dependent kinases (CDK), especially THZ1, a covalent inhibitor of CDK7. THZ1 demonstrated pronounced antineoplastic activities both in vitro and in vivo. An integrative analysis using both whole-transcriptome sequencing and chromatin immunoprecipitation sequencing pinpointed oncogenic transcriptional amplification mediated by super-enhancers (SE) as a key mechanism underlying the vulnerability of NPC cells to THZ1 treatment. Further characterization of SE-mediated networks identified many novel SE-associated oncogenic transcripts, such as BCAR1, F3, LDLR, TBC1D2, and the long noncoding RNA TP53TG1. These transcripts were highly and specifically expressed in NPC and functionally promoted NPC malignant phenotypes. Moreover, DNA-binding motif analysis within the SE segments suggest that several transcription factors (including ETS2, MAFK, and TEAD1) may help establish and maintain SE activity across the genome. Taken together, our data establish the landscape of SE-associated oncogenic transcriptional network in NPC, which can be exploited for the development of more effective therapeutic regimens for this disease.
AB - Nasopharyngeal carcinoma (NPC) is an invasive cancer with particularly high incidence in Southeast Asia and Southern China. The pathogenic mechanisms of NPC, particularly those involving epigenetic dysregulation, remain largely elusive, hampering clinical management of this malignancy. To identify novel druggable targets, we carried out an unbiased high-throughput chemical screening and observed that NPC cells were highly sensitive to inhibitors of cyclin-dependent kinases (CDK), especially THZ1, a covalent inhibitor of CDK7. THZ1 demonstrated pronounced antineoplastic activities both in vitro and in vivo. An integrative analysis using both whole-transcriptome sequencing and chromatin immunoprecipitation sequencing pinpointed oncogenic transcriptional amplification mediated by super-enhancers (SE) as a key mechanism underlying the vulnerability of NPC cells to THZ1 treatment. Further characterization of SE-mediated networks identified many novel SE-associated oncogenic transcripts, such as BCAR1, F3, LDLR, TBC1D2, and the long noncoding RNA TP53TG1. These transcripts were highly and specifically expressed in NPC and functionally promoted NPC malignant phenotypes. Moreover, DNA-binding motif analysis within the SE segments suggest that several transcription factors (including ETS2, MAFK, and TEAD1) may help establish and maintain SE activity across the genome. Taken together, our data establish the landscape of SE-associated oncogenic transcriptional network in NPC, which can be exploited for the development of more effective therapeutic regimens for this disease.
UR - http://www.scopus.com/inward/record.url?scp=85037706403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037706403&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-17-1143
DO - 10.1158/0008-5472.CAN-17-1143
M3 - Article
C2 - 28951465
AN - SCOPUS:85037706403
SN - 0008-5472
VL - 77
SP - 6614
EP - 6626
JO - Cancer Research
JF - Cancer Research
IS - 23
ER -